Lupin collaborate with Amman Pharma for marketing, commercialization of Ranibizumab in Middle East region
Mumbai: Global Pharma major Lupin Limited has partnered with Amman Pharmaceuticals Industries, a pharmaceutical manufacturer with operations across the MENA region and other global markets, for exclusive marketing and commercialization of Ranibizumab, a biosimilar of Lucentis, in the Middle East region, including select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries.
"Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region," the Company stated in a release.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
“Our aim is to be at the forefront of transforming patient’s lives and building a healthier, brighter future for all. We are excited about the partnership with Amman Pharma to bring Ranibizumab to the MENA region,” said Nilesh Gupta, Managing Director, Lupin. “We aim to empower patients by offering timely and widespread access to cutting-edge biologic medication at affordable costs. Our successful development of biosimilar Ranibizumab stands as testament to this commitment,” said Dr. Cyrus Karkaria, President Biotechnology, Lupin. “Our mission in collaborating with Amman Pharma is to provide patients with advanced biologics that hold the promise of reshaping their health journey.”
Dr. Fadi Alatrash, General Manager of Amman Pharma said, “We are proud to partner with Lupin, a world-leading biopharmaceutical company, to market and commercialize Ranibizumab. This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region. It also expands our biosimilar portfolio and strengthens our position in the niche Ophthalmology market.”
Read also: Lupin gets tentative USFDA nod for Canagliflozin, Metformin Hydrochloride ER tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.